Neurons as targets for T cells in the nervous system

Trends in Neurosciences

Volumn 36, Issue 6, 2013, Pages 315-324

  Liblau, Roland S ^a,b,c   Gonzalez Dunia, Daniel ^a,b   Wiendl, Heinz ^d   Zipp, Frauke ^e  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Central nervous system; Encephalomyelitis; Inflammation; Neuron; T cell

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; DENDRITE; EFFECTOR CELL; GRANULE CELL; GRAY MATTER; HUMAN; NERVE CELL; NERVE CELL LESION; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE FIBER; NERVE FIBER TRANSPORT; NEURITE; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; SENSORY NERVE CELL; SUBARACHNOID SPACE; SYNAPTIC TRANSMISSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TH1 CELL; TH17 CELL; VIRUS ENCEPHALITIS; WHITE MATTER;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; ENCEPHALITIS, VIRAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; NEURONS; T-LYMPHOCYTE SUBSETS;

EID: 84878569202     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.01.008     Document Type: Review

References (100)

1. Galea I., et al. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
2. Ransohoff R.M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012, 12:623-635.
3. Tan I.L., et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011, 77:1061-1067.
4. Cose S., et al. Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur. J. Immunol. 2006, 36:1423-1433.
5. Schneider-Hohendorf T., et al. Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. Eur. J. Immunol. 2010, 40:3581-3590.
6. Na S.Y., et al. Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity 2012, 37:134-146.
7. Kipnis J., et al. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 2012, 12:663-669.
8. Arima Y., et al. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 2012, 148:447-457.
9. Reboldi A., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
10. Yednock T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
11. Ifergan I., et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain 2011, 134:3560-3577.
12. Young K.G., et al. CD8+ T cells primed in the periphery provide time-bound immune-surveillance to the central nervous system. J. Immunol. 2011, 187:1192-1200.
13. Galea I., et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204:2023-2030.
14. Rothhammer V., et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J. Exp. Med. 2011, 208:2465-2476.
15. Schulze-Topphoff U., et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 2009, 15:788-793.
16. Odoardi F., et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
17. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
18. McConnell M.J., et al. H2-K(b) and H2-D(b) regulate cerebellar long-term depression and limit motor learning. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6784-6789.
19. Shatz S.C., et al. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009, 64:40-45.
20. Needleman L.A., et al. MHC class I molecules are present both pre- and postsynaptically in the visual cortex during postnatal development and in adulthood. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16999-17004.
21. Maehlen J., et al. Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci. Lett. 1988, 92:8-13.
22. Bien C.G., et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann. Neurol. 2002, 51:311-318.
23. Höftberger R., et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
24. Foster J.A., et al. Induced neuronal expression of class I major histocompatibility complex mRNA in acute and chronic inflammation models. J. Neuroimmunol. 2002, 131:83-91.
25. Chevalier G., et al. Neurons are MHC class I-dependent targets for CD8 T cells upon neurotropic viral infection. PLoS Pathog. 2011, 7:e1002393.
26. Neumann H., et al. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J. Exp. Med. 1997, 185:305-316.
27. Medana I., et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001, 159:809-815.
28. Delhaye S., et al. Neurons produce type I interferon during viral encephalitis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7835-7840.
29. Kaltschmidt C., et al. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9618-9622.
30. Diaz-Hernandez M., et al. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 2003, 23:11653-11661.
31. Kremer M., et al. Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J. Immunol. 2010, 185:5549-5560.
32. Meuth S.G., et al. Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J. Neurosci. 2009, 29:15397-15409.
33. Siffrin V., et al. In vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010, 33:424-436.
34. McGavern D.B., Kang S.S. Illuminating viral infections in the nervous system. Nat. Rev. Immunol. 2011, 11:318-329.
35. Binah O. Cytotoxic lymphocytes and cardiac electrophysiology. J. Mol. Cell. Cardiol. 2002, 34:1147-1161.
36. Berridge M.J. Neuronal calcium signaling. Neuron 1998, 21:13-26.
37. Mizuno T., et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J. 2008, 22:1797-1806.
38. Suidan H.S., et al. Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:8112-8116.
39. Thayer T.C., et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes 2011, 60:2144-2151.
40. Medana I.M., et al. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur. J. Immunol. 2000, 30:3623-3633.
41. Huse M., et al. Shouts, whispers and the kiss of death: directional secretion in T cells. Nat. Immunol. 2008, 9:1105-1111.
42. Waxman S.G., et al. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 2006, 7:932-941.
43. Aktas O., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005, 46:421-432.
44. Vogt J., et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol. 2009, 66:310-322.
45. Nitsch R., et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 2004, 24:2458-2464.
46. Pitt D., et al. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6:67-70.
47. Smith T., et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 2000, 6:62-66.
48. Nikic I., et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 2011, 17:495-499.
49. Pool M., et al. Neurite outgrowth is differentially impacted by distinct immune cell subsets. Mol. Cell. Neurosci. 2012, 49:68-76.
50. Kerschensteiner M., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J. Exp. Med. 1999, 189:865-870.
51. Linker R.A., et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010, 133:2248-2263.
52. Herges K., et al. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS ONE 2011, 6:e25456.
53. Liblau R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J. Neurol. Sci. 2009, 287:S17-S23.
54. Moalem G., et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 1999, 5:49-55.
55. Ishii H., et al. Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury. Cell Death Dis. 2012, 3:e363.
56. Walsh J.T., Kipnis J. Regulatory T cells in CNS injury: the simple, the complex and the confused. Trends Mol. Med. 2011, 17:541-547.
57. Gendelman H.E., et al. Neuroprotective activities of regulatory T cells. Trends Mol. Med. 2011, 12:687-688.
58. Rook G.A., et al. Lymphocytes in neuroprotection, cognition and emotion: is intolerance really the answer?. Brain Behav. Immun. 2011, 25:591-601.
59. Anderton S.M., Liblau R. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr. Opin. Neurol. 2008, 21:248-254.
60. Wiendl H., et al. CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. J. Neuroinflammation 2012, 9:41.
61. Liu Y., et al. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 2006, 12:518-525.
62. Bhat R., et al. Inhibitory role for GABA in autoimmune inflammation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2580-2585.
63. Affaticati P., et al. Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells. Cell Death Differ. 2011, 18:99-108.
64. Vincent A., et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011, 10:759-772.
65. Melzer N., et al. Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr. Opin. Neurol. 2012, 25:341-348.
66. McKeon A., Pittock S.J. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol. 2011, 122:381-400.
67. Bien C.G., et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012, 135:1622-1638.
68. Verschuuren J., et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996, 91:519-525.
69. Giometto B., et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol. Appl. Neurobiol. 1997, 23:468-474.
70. Bauer J., et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann. Neurol. 2007, 62:67-80.
71. Schwab N., et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 2009, 132:1236-1246.
72. Shrestha B., et al. Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system. J. Virol. 2007, 81:11749-11757.
73. Zhang B., et al. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 2008, 180:2641-2649.
74. Shrestha B., et al. CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J. Virol. 2012, 86:8937-8948.
75. Verjans G.M., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3496-3501.
76. Knickelbein J.E., et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008, 322:268-271.
77. Wakim L.M., et al. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17872-17879.
78. Brochard V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
79. Reynolds A.D., et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 2010, 184:2261-2271.
80. Reynolds A.D., et al. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol. 2009, 182:4137-4149.
81. Hauser S.L., et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 1986, 19:578-587.
82. Bitsch A., et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123:1174-1183.
83. Junker A., et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130:2789-2799.
84. Peterson J.W., et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50:389-400.
85. Bo L., et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 2003, 9:323-331.
86. Traugott U., et al. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983, 219:308-310.
87. Lucchinetti C.F., et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365:2188-2197.
88. Siffrin V., et al. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010, 33:202-210.
89. Sofroniew M.V., et al. Distribution of degeneration of cholinergic neurons in the septum following axotomy in different portions of the fimbria-fornix: a correlation between degree of cell loss and proximity of neuronal somata to the lesion. J. Chem. Neuroanat. 1988, 1:327-337.
90. Dalton C.M., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004, 127:1101-1107.
91. Inglese M., et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004, 21:1825-1829.
92. Dutta R., Trapp B.D. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 2011, 93:1-12.
93. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
94. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium.
95. Gregory A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.
96. Sobbe M., et al. Induction of degenerative brain lesions after adoptive transfer of brain lymphocytes from Borna disease virus-infected rats: presence of CD8+ T cells and perforin mRNA. J. Virol. 1997, 71:2400-2407.
97. Scheikl T., et al. Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J. Immunol. 2012, 188:4731-4735.
98. Fontana A., et al. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss?. Brain 2010, 133:1300-1311.
99. Dauvilliers, Y. et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurology (in press).
100. Holmoy T. T cells in amyotrophic lateral sclerosis. Eur. J. Neurol. 2008, 15:360-366.